CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Morgan Stanley Adjusts Price Target Biogen to $222 From $224, Maintains Equalweight Rating

Neutral
AI Analysis

Summary

Morgan Stanley lowered its price target for Biogen to $222 from $224 while maintaining an Equalweight rating, representing a minor downward adjustment to valuation.

Importance:2/10
Sentiment:
-0.10
price_target_adjustmentanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on July 8, 2026 9:18 AM

Read Original